关键词：肺部递送；全身性治疗；活性；非侵入性递送；优选循环；高通透率
摘 要：Pulmonary delivery of drugs leads to the deposition of drugs in the lungs and subsequent local or systemic therapeutic activity. The pulmonary route of administration for the non-invasive delivery of drugs is mostly preferred because of the large surface area for absorption, high blood circulation, and high permeability rate. Pulmonary drug delivery offers various advantages over peroral routes, such as bypass of hepatic first-pass metabolism, quick onset of action, and low enzymatic activity. Pulmonary delivery of drugs can be achieved by intranasal administration or oral inhalative administration, the latter being more effective. Oral inhalative administration includes intratracheal inhalation and intratracheal instillation. Oral inhalation delivers the aerosolized drug using devices such as MDIs (or pMDIs), PDIs, and nebulizers. Drugs administered by this route are deposited in the respiratory tract via inertial impaction, gravitational sedimentation, and diffusion. The effective delivery of drugs via the pulmonary route requires an optimized combination of drug, its formulation, and device.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Market Segmentation by Product Type

08. MDIs

08.1 Introduction

08.2 Basic Components

08.3 Drug Deposition

08.4 Pros and Cons of MDIs

08.5 Market Size and Forecast

09. DPIs

09.1 Introduction

09.2 Segmentation of DPIs by Product Type

09.3 Basic Components

09.4 Drug Delivery

09.5 Drug Deposition

09.6 Pros and Cons of DPIs

09.7 Market Size and Forecast

10. Nebulizers

10.1 Introduction

10.2 Pros and Cons of Nebulizers

10.3 Segmentation of Nebulizers by Product Type

10.4 Jet Nebulizers

10.5 Ultrasonic Nebulizers

10.6 Market Size and Forecast

11. Geographical Segmentation

11.1 Pulmonary Drug Delivery Systems Market in

Americas

11.1.1 Market Size and Forecast

11.2 Pulmonary Drug Delivery Systems Market in

EMEA Region

11.2.1 Market Size and Forecast

11.3 Pulmonary Drug Delivery Systems Market in

APAC Region

11.3.1 Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Share Analysis 2014

19.2.1 AstraZeneca.

19.2.2 Boehringer Ingelheim

19.2.3 GlaxoSmithKline

19.2.4 Novartis

19.2.5 Philips Healthcare

19.3 Other Prominent Vendors

20. Key Vendor Analysis

20.1 AstraZeneca

20.1.1 Key Facts

20.1.2 Business Overview

20.1.3 Business Segmentation by Revenue 2013

20.1.4 Business Segmentation by Revenue 2011-2013

20.1.5 Revenue by Geographical Segmentation

20.1.6 Business Strategy

20.1.7 Key Developments

20.1.8 SWOT Analysis

20.2 Boehringer Ingelheim

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation by Revenue 2013

20.2.4 Business Segmentation by Revenue 2012 and 2013

20.2.5 Revenue by Geographical Segmentation 2013

20.2.6 Business Strategy

20.2.7 Recent Developments

20.2.8 SWOT Analysis

20.3 GlaxoSmithKline

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation

20.3.4 Business Segmentation by Revenue 2012 and 2013

20.3.5 Revenue by Geographical Segmentation

20.3.6 Pipeline Products

20.3.7 Business Strategy

20.3.8 Key Information

20.3.9 SWOT Analysis

20.4 Novartis

20.4.1 Key Facts

20.4.2 Business Description

20.4.3 Business Segmentation

20.4.4 Revenue by Business Segmentation 7

20.4.5 Revenue Comparison 2012 and 2013

20.4.6 Revenue by Geographical Segmentation

20.4.7 Business Strategy

20.4.8 Key Developments

20.4.9 SWOT Analysis

20.5 Philips Healthcare

20.5.1 Key Facts

20.5.2 Business Overview

20.5.3 Revenue by Business Segmentation 2012

20.5.4 Revenue by Geographical Segmentation

20.5.5 Business Strategy

20.5.6 Key Developments

20.5.7 SWOT Analysis

21. Other Reports in this Series